Cargando…
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses, has been proposed to enhance the immune resp...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294770/ https://www.ncbi.nlm.nih.gov/pubmed/37140889 http://dx.doi.org/10.1080/21645515.2023.2206360 |
_version_ | 1785063262309580800 |
---|---|
author | Tawinprai, Kriangkrai Jungsomsri, Pawornrath Pinijnai, Onnicha Tavonvunchai, Fahsiri Lievjaroen, Anchisa Suwannaroj, Paphada Siripongboonsitti, Taweegrit Porntharukchareon, Thachanun Sornsamdang, Gaidganok Ungtrakul, Teerapat |
author_facet | Tawinprai, Kriangkrai Jungsomsri, Pawornrath Pinijnai, Onnicha Tavonvunchai, Fahsiri Lievjaroen, Anchisa Suwannaroj, Paphada Siripongboonsitti, Taweegrit Porntharukchareon, Thachanun Sornsamdang, Gaidganok Ungtrakul, Teerapat |
author_sort | Tawinprai, Kriangkrai |
collection | PubMed |
description | The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses, has been proposed to enhance the immune response. We aimed to compare the immunogenicity and safety of a heterologous prime-boost vaccination using an inactivated COVID-19 vaccine and AZD1222 vaccine with that of a homologous vaccination using AZD1222. This pilot involved 164 healthy volunteers without prior SARS-CoV-2 infection aged 18 years or older assigned to receive either the heterologous or homologous vaccination. The results showed that the heterologous approach was safe and well-tolerated, although the reactogenicity of the heterologous approach was higher. At 4 weeks after receiving the booster dose, the heterologous approach elicited a non-inferior immune response compared to the homologous approach in neutralizing antibody and cell-mediated immune response. The percentage of inhibition was 83.88 (79.72–88.03) in the heterologous and 79.88 (75.50–84.25) in the homologous group, a mean difference of 4.60 (−1.67–10.88). The geometric mean of interferon-gamma was 1072.53 mIU/mL (799.29–1439.18) in the heterologous group and 867.67 mIU/mL (671.94–1120.40) in the homologous group, a GMR of 1.24 (0.82–1.85). However, the binding antibody test of the heterologous group was inferior to the homologous group. Our findings suggest that the use of heterologous prime-boost vaccination with different types of COVID-19 vaccines is a viable strategy, especially in settings where vaccine supply is limited or where vaccine distribution is challenging. |
format | Online Article Text |
id | pubmed-10294770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-102947702023-06-28 Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study Tawinprai, Kriangkrai Jungsomsri, Pawornrath Pinijnai, Onnicha Tavonvunchai, Fahsiri Lievjaroen, Anchisa Suwannaroj, Paphada Siripongboonsitti, Taweegrit Porntharukchareon, Thachanun Sornsamdang, Gaidganok Ungtrakul, Teerapat Hum Vaccin Immunother Coronavirus The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses, has been proposed to enhance the immune response. We aimed to compare the immunogenicity and safety of a heterologous prime-boost vaccination using an inactivated COVID-19 vaccine and AZD1222 vaccine with that of a homologous vaccination using AZD1222. This pilot involved 164 healthy volunteers without prior SARS-CoV-2 infection aged 18 years or older assigned to receive either the heterologous or homologous vaccination. The results showed that the heterologous approach was safe and well-tolerated, although the reactogenicity of the heterologous approach was higher. At 4 weeks after receiving the booster dose, the heterologous approach elicited a non-inferior immune response compared to the homologous approach in neutralizing antibody and cell-mediated immune response. The percentage of inhibition was 83.88 (79.72–88.03) in the heterologous and 79.88 (75.50–84.25) in the homologous group, a mean difference of 4.60 (−1.67–10.88). The geometric mean of interferon-gamma was 1072.53 mIU/mL (799.29–1439.18) in the heterologous group and 867.67 mIU/mL (671.94–1120.40) in the homologous group, a GMR of 1.24 (0.82–1.85). However, the binding antibody test of the heterologous group was inferior to the homologous group. Our findings suggest that the use of heterologous prime-boost vaccination with different types of COVID-19 vaccines is a viable strategy, especially in settings where vaccine supply is limited or where vaccine distribution is challenging. Taylor & Francis 2023-05-04 /pmc/articles/PMC10294770/ /pubmed/37140889 http://dx.doi.org/10.1080/21645515.2023.2206360 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Coronavirus Tawinprai, Kriangkrai Jungsomsri, Pawornrath Pinijnai, Onnicha Tavonvunchai, Fahsiri Lievjaroen, Anchisa Suwannaroj, Paphada Siripongboonsitti, Taweegrit Porntharukchareon, Thachanun Sornsamdang, Gaidganok Ungtrakul, Teerapat Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study |
title | Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study |
title_full | Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study |
title_fullStr | Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study |
title_full_unstemmed | Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study |
title_short | Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study |
title_sort | immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated covid-19 and chadox1 ncov-19 (azd1222) vaccines, a quasi-experimental study |
topic | Coronavirus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294770/ https://www.ncbi.nlm.nih.gov/pubmed/37140889 http://dx.doi.org/10.1080/21645515.2023.2206360 |
work_keys_str_mv | AT tawinpraikriangkrai immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT jungsomsripawornrath immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT pinijnaionnicha immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT tavonvunchaifahsiri immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT lievjaroenanchisa immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT suwannarojpaphada immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT siripongboonsittitaweegrit immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT porntharukchareonthachanun immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT sornsamdanggaidganok immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy AT ungtrakulteerapat immunogenicityandreactogenicityofheterologousprimeboostvaccinationwithinactivatedcovid19andchadox1ncov19azd1222vaccinesaquasiexperimentalstudy |